Leadartech

Ningbo Leadartech Biotechnology Co., Ltd. (Leadartech) is a biotechnology company that integrates chemical proteomics, automation, and artificial intelligence to accelerate drug discovery and cell therapy research. The company has developed core technologies including the In-Vivo Target Response Analysis Platform (INTRAP), which enables high-throughput drug screening within living cells, organoids, and other live systems without requiring protein purification. Furthermore, Leadartech utilizes light-affinity and activity-based protein profiling (PAL-AfBPP and ABPP) to identify drug targets, map binding sites, and explore protein interaction networks. To support these efforts, the firm has established an extensive library of chemical probes and is constructing a large-scale database of human protein-probe binding data.

Beyond its R&D platform, Leadartech designs and manufactures laboratory automation equipment, such as automated cell culture systems and sample preparation systems, to address the complexity of chemical proteomics workflows. These proprietary automated systems, including the Target Space Station, are designed to improve experimental throughput, data accuracy, and reproducibility. By providing specialized technology and services to universities, research institutes, and pharmaceutical companies globally, Leadartech aims to overcome challenges associated with hard-to-drug targets and digitalize the drug discovery process. Their multi-disciplinary team has secured numerous patents and recognitions, including being designated as a high-tech enterprise.